Plaque Psoriasis in 68 Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2030
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Plaque Psoriasis (PsO) market through 2030.
GlobalData estimated the value of the global PsO market to be $11.6 billion across the 7MM in 2020. By 2030, PsO sales across are expected to grow to $30.1 billion, representing a compound annual growth rate (CAGR) of 10.0% over the 10-year forecast period. Major drivers of growth in the PsO market over the forecast period include a steady increase in total diagnosed prevalence across the 7MM and launches of five new pipeline agents: icotrokinra (JNJ-2113), sonelokimab, orismilast, piclidenoson, and TAK-279
Across the 68 markets, sales in the PsO market were $16.4billion in 2020, growing to $44.0 billion in 2030. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 70.5% and 68.4% of 68-market sales in 2020 and 2030, respectively.
Scope
Overview of Plaque Psoriasis (PsO), including epidemiology, symptoms, diagnosis, and disease management.
Annualized Plaque Psoriasis (PsO) therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PsO therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PsO treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global Plaque Psoriasis (PsO) therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
- The greatest drivers of growth in the global PsO market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many 7MM countries.
- The main barriers to growth in the PsO market include the patent expiration of several key biologics and small molecules.
- Among the late-stage innovator pipeline products, three are injectable biologics, three are oral small molecules, and two are topical small molecules.
- The most important unmet needs in the PsO market are increased access to therapies as well as therapies that can target multiple disease domains.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM and 68M Plaque Psoriasis (PsO) therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM and 68M Plaque Psoriasis (PsO) therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Organon
Leo Pharmaceuticals
Arcutis Biotherapeutics
AbbVie
BMS
Janssen
Johnson & Johnson
Novartis
UCB
AstraZeneca
Sun Pharma
Bausch Health
Union Therapeutics
Can-Fite Biopharma
Alumis
Lilly
Takeda
MoonLake Immunotherapeutics
Bristol-Myers Squibb Co
Novartis AG
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Co Ltd
Sanofi
AbbVie Inc
UCB Inc
Johnson and Johnson
Inc.
Union Therapeutics AS
Janssen
LEO Pharma
Dermavant Sciences Inc
Arcutis Biotherapeutics Inc
MoonLake Immunotherapeutics
Bausch Health
Table of Contents
Table
Figures
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Plaque Psoriasis (Psoriasis Vulgaris) reports